Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Ambrx Biopharma Inc. to Present at Upcoming Investor Conferences

Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced that Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx, will present at two upcoming investor conferences in May.

Bank of America 2022 Healthcare Conference. Dr. Tian will participate in an analyst led fireside chat on Wednesday, May 11 at 12:00 PM Pacific Time / 3:00 PM Eastern Time.

H.C. Wainwright Global Investment Conference. Dr. Tian will conduct a pre-recorded presentation that will be available on-demand on Tuesday, May 24 at 4:00 AM Pacific Time / 7:00 AM Eastern Time.

Interested parties can access the live and pre-recorded webcasts for these conferences from the Investor Relations section of the company's website at www.Ambrx.com. The webcast replays will be available after the conclusion of the respective presentations for approximately 90 days.

About Ambrx Biopharma Inc. (Ambrx)

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, Ambrx has clinical collaborations with multiple partners, for drug candidates generated using Ambrx technology. For more information, please visit www.ambrx.com.

These press releases may also interest you

at 12:05
Oncologica, a leading genetic cancer and viral testing laboratory based in Cambridge UK, has launched its new Prostatefocus cancer genetic screening test that identifies men at increased risk of developing prostate cancer. Prostate cancer is the...

at 12:00
The Department of Veterans Affairs (VA) has awarded GovCIO the Health Services Portfolio Technical Management and Strategic Solutioning Support contract, which has a total value of $390 million....

at 11:30
ClexBio, an early-stage biotech company developing next-generation tissue engineered grafts for transplant, is announcing the appointment of two new members to its Board of Directors. Joining the board with immediate effect are Andreas Lehmann as...

at 11:30
According to the new market research report "Tissue Diagnostics Market by Product (Antibodies, Kits, Slide Staining System, Tissue Processing System), Technology(ISH, IHC, Special Staining), Disease(Breast Cancer, NSCLC, Lymphoma), End User...

at 11:05
The direct-to-consumer genetic testing market is fragmented, and the vendors are deploying growth strategies such as market expansion, investments, and distribution networks to compete in the market....

at 10:47
Hemcheck Sweden AB has signed a distributor agreement with SDO Medical regarding the Spanish market. The agreement entails an initial evaluation period of 6 months and a requirement for a first order. - SDO Medical has shown strong interest and has...

News published on 6 may 2022 at 16:10 and distributed by: